Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marilyn Jerome

Gynecology Washington, DC Medical Doctor

NPI 1558415414 CMS profile 342615

5215 Loughboro Rd Nw, Suite 500, Washington, DC 20016

Open in the dashboard

General payments

$13,578

88 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marilyn Jerome of Washington, DC is reported in the CMS Open Payments database as having received $13,578 across 88 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,000 2
2024 General $4,525 4
2023 General $6,829 19
2022 General $206 11
2021 General $80 4
2020 General $199 11
2019 General $739 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marilyn Jerome
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to Marilyn Jerome were reported at $1,000. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year Marilyn Jerome Gynecology median Middle half National median
2019 $739 $199 $66–$472 $163
2020 $199 $114 $42–$287 $114
2021 $80 $141 $42–$430 $132
2022 $206 $173 $52–$532 $149
2023 $6,829 $170 $57–$501 $160
2024 $4,525 $157 $50–$424 $164
2025 $1,000 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $11,978 21 payments
  2. AbbVie, Inc. $228 12 payments
  3. Pfizer Inc. $222 14 payments
  4. Renovia Inc $161 2 payments
  5. Myriad Women's Health, Inc. $156 1 payment
  6. Astellas Pharma Global Development $118 1 payment
  7. Hologic, LLC $90 2 payments
  8. Millicent US Inc $81 5 payments
  9. TherapeuticsMD, Inc. $53 3 payments
  10. CooperSurgical, Inc. $51 3 payments
  11. Other $438 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,400 7 payments
  2. Food and Beverage $2,028 77 payments
  3. Travel and Lodging $133 3 payments
  4. Education $16 1 payment
Products named General payments · program years 2019–2025
  1. Veozah $11,569 14 payments
  2. PREMARIN $282 17 payments
  3. ESTRING $202 13 payments
  4. COLOGUARD $163 11 payments
  5. Leva Pelvic Floor Trainer $161 2 payments
  6. myRisk $156 1 payment
  7. ORILISSA $139 7 payments
  8. MYFEMBREE $89 4 payments
  9. MYRBETRIQ $88 5 payments
  10. ORIAHNN $80 4 payments
  11. Other $953 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

446

Median for Obstetrics & Gynecology: 65

Drug cost

$81,127

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

48.2%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prolia Denosumab Brand 13 $22,628
Estradiol Generic 138 $15,670
Premarin Estrogens, Conjugated Brand 29 $13,507
Yuvafem Estradiol Brand 43 $9,259
Estring Estradiol Brand 18 $9,193
Estradiol (Twice Weekly) Estradiol Brand 32 $4,091
Progesterone Progesterone, Micronized Brand 45 $1,976
Raloxifene Hcl Generic 24 $1,713
Estradiol (Once Weekly) Estradiol Brand 16 $1,229
Alendronate Sodium Generic 69 $1,063

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $4,125
$4,125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

88 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecology in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record